Our top pick for
China Biologic Products Holdings Inc is a biotechnology business based in the US. China Biologic Products shares (CBPO) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||$110.42 - $120.01|
|50-day moving average||$117.97|
|200-day moving average||$117.60|
|Wall St. target price||$102.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$3.82|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing China Biologic Products stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of China Biologic Products's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
China Biologic Products's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, China Biologic Products shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
China Biologic Products's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.53. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into China Biologic Products's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
China Biologic Products's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $222.6 million.
The EBITDA is a measure of a China Biologic Products's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$524.4 million|
|Operating margin TTM||37.26%|
|Gross profit TTM||$344.4 million|
|Return on assets TTM||5.82%|
|Return on equity TTM||9.25%|
|Market capitalisation||$4.6 billion|
TTM: trailing 12 months
There are currently 781,133 China Biologic Products shares held short by investors – that's known as China Biologic Products's "short interest". This figure is 13.5% down from 902,696 last month.
There are a few different ways that this level of interest in shorting China Biologic Products shares can be evaluated.
China Biologic Products's "short interest ratio" (SIR) is the quantity of China Biologic Products shares currently shorted divided by the average quantity of China Biologic Products shares traded daily (recently around 108040.52558783). China Biologic Products's SIR currently stands at 7.23. In other words for every 100,000 China Biologic Products shares traded daily on the market, roughly 7230 shares are currently held short.
However China Biologic Products's short interest can also be evaluated against the total number of China Biologic Products shares, or, against the total number of tradable China Biologic Products shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case China Biologic Products's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 China Biologic Products shares in existence, roughly 20 shares are currently held short) or 0.0345% of the tradable shares (for every 100,000 tradable China Biologic Products shares, roughly 35 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against China Biologic Products.
Find out more about how you can short China Biologic Products stock.
We're not expecting China Biologic Products to pay a dividend over the next 12 months.
Over the last 12 months, China Biologic Products's shares have ranged in value from as little as $110.42 up to $120.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while China Biologic Products's is 0.4242. This would suggest that China Biologic Products's shares are less volatile than average (for this exchange).
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.